search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


34 resulaten gevonden voor Acute Myeloid Leukemia (AML) in trials

Safety of TEG001 in patients with r/r AML, high-risk MDS or MM
- TRIAL ID
NTR6541
- ACRONYMTEG001
A phase I/II feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with Flt3-ITD AML
- TRIAL ID
NTR6511
- ACRONYMHOVON 148 AML
Real world data collection and population-based analysis of incidence of patients with acute myeloid leukemia (AML).
- TRIAL ID
NTR6105
- ACRONYM
A phase I/II post-cord blood HCT dendritic cell vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial
- TRIAL ID
NTR6055
- ACRONYMU-DANCE-anti-AML Trial
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients.
- TRIAL ID
NTR6017
- ACRONYMHOVON 135 AML
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged >66 years .
- TRIAL ID
NTR5902
- ACRONYMHOVON 103 AML Selinexor
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
- TRIAL ID
NTR5644
- ACRONYMDecitabine-cytarabine
Natural killer cell infusion after stem cell transplantation for leukemia
- TRIAL ID
NTR4403
- ACRONYMIL-15 activated NK cells
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)
- TRIAL ID
NTR4376
- ACRONYMHOVON 132 AML
FLAMSA chemotherapy directly followed by donor stem cell transplantation in elderly patients with acute myeloid leukemia (AML) or high risk myelodysplasia (MDS)
- TRIAL ID
NTR4014
- ACRONYMFLAMSA TCD NMA AlloSCT
Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemia.
- TRIAL ID
NTR3927
- ACRONYM
Prospective study of quantitative molecular minimal residual disease (MRD) monitoring in pediatric acute myeloid leukemia (AML).
- TRIAL ID
NTR3482
- ACRONYMQMRD in AML
A study on the influence of dynamic light on sleep an circadian rhythm, in long-stay patients on a haematology ward.
- TRIAL ID
NTR3217
- ACRONYMDynamic light study
NK cells as post consolidation therapie in AML.
- TRIAL ID
NTR2818
- ACRONYMPMLA25
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
- TRIAL ID
NTR2477
- ACRONYMHOVON 103 AML Tosedostat
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
- TRIAL ID
NTR2294
- ACRONYMHOVON 103 AML Lenalidomide
Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS =>1.5).
- TRIAL ID
NTR2187
- ACRONYMHOVON 102 AML
Dutch- Belgian pediatric acute myeloid leukemia (AML) protocol.
- TRIAL ID
NTR2120
- ACRONYMDB-AML-01
A phase II study of clofarabine in combination with cytarabine and daunoxome for children with acute myeloid leukemia withour other treatment options.
- TRIAL ID
NTR1880
- ACRONYMCLARA-DNX
6-MP studie.
- TRIAL ID
NTR1811
- ACRONYM6-MP in AML
Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (>= 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t).
- TRIAL ID
NTR1810
- ACRONYMHOVON 97 AML
Typhlitis study.
- TRIAL ID
NTR1800
- ACRONYMTyphlitis in AML
Mylotarg as salvage treatment for children with relapsed acute myeloid leukemia.
- TRIAL ID
NTR1680
- ACRONYMRelapsed AML 2001/02
Wilms tumor gene (WT1) mRNA¨Ctransfected autologous dendritic cell vaccination for patients with acute myeloid leukemia. A pilot dose escalation study.
- TRIAL ID
NTR1608
- ACRONYMWT1-1
A phase II study to assess engraftment and engraftment kinetics after double cord blood transplantation with a reduced-intensity conditioning regimen in patients eligible for allogeneic stem cell transplantation lacking a matched unrelated donor.
- TRIAL ID
NTR1573
- ACRONYMEngraftment after double cord blood transplantation.
Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS >= 1.5)
- TRIAL ID
NTR1446
- ACRONYMHOVON 92 AML
A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.
- TRIAL ID
NTR904
- ACRONYMHOVON 81 AML
Reduced intensity chemotherapy given with and without Imatinib Mesylate in patients >= 60 years considered unfit for standard chemotherapy with previously untreated Acute Myeloid Leukemia (AML) and refractory anemia with excess of Blasts (RAEB, RAEB-T); A randomized phase II study.
- TRIAL ID
NTR655
- ACRONYMHOVON / SAKK AML - 67
Protection against chemotherapy induced damage in the digestive tract in childhood cancer patients.
- TRIAL ID
NTR401
- ACRONYMN/A
An open label randomized controlled study in elderly subjects with previously untreated acute myelogenous leukaemia, comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833.
- TRIAL ID
NTR360
- ACRONYMHOVON 31 AML / Novartis PSC C 302-E-00
Risk adapted treatment of acute myelocytic leukemia (AML).
- TRIAL ID
NTR291
- ACRONYMHOVON 29 AML/SAKK 30/95
Randomized induction and post induction therapy in adult patients (<= 60 yrs of age) with acute myelocytic leukemia (AML) or refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score >= 1.5.
- TRIAL ID
NTR230
- ACRONYMHOVON/SAKK 42 AML
Randomized induction and post induction therapy in older patients (>= 61 yrs of age) with acute myelocytic leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t).
- TRIAL ID
NTR212
- ACRONYMHOVON 43 AML / SAKK 30/01
TRIAL Relapsed AML 2001/01.
- TRIAL ID
NTR136
- ACRONYMRelapsed AML 2001/01